ULBP1 and osteosarcoma: Decitabine could upregulate major histocompatibility complex class I-related chains B and UL16-binding protein 1 expression, and combination treatment involving γδ T cell immunotherapy and decitabine could be used to enhance the cytotoxic killing of osteosarcoma cells by γδ T cells (71).